NIH Statement: Calcium Channel Blockers And Breast Cancer Risk

October 15, 1997

A new analysis linking some calcium channel blockers to an increased risk of breast cancer in older women appears in the October 15 issue of the journal Cancer. According to the study, postmenopausal women who took calcium channel blockers had twice the risk of developing breast cancer than other women. The overall cancer risk was not increased.

Calcium channel blockers are used to treat high blood pressure and heart disease. No association was found between other high blood pressure medications and breast cancer risk.

The analysis relates primarily to short-acting calcium channel blockers and not the longer-acting variety taken by most Americans. Longer-acting varieties have a slower absorption rate and are taken only once a day.

The analysis used data on 3,198 women, aged 65 and older, observed annually between 1989-94. The data were part of a larger Cardiovascular Health Study, funded by the National Heart, Lung, and Blood Institute (NHLBI).

The analysis may raise concerns among those taking calcium channel blockers. The NHLBI, National Cancer Institute (NCI), and National Institute on Aging (NIA), all units of the National Institutes of Health, want to urge patients not to stop taking a calcium channel blocker without consulting their physician. Officials at these Institutes note that the dangers of uncontrolled high blood pressure may outweigh a possible cancer risk found in the study.

They also stress that these are preliminary findings and come from an observational study with a small number of cases. The findings do not establish a causal relationship between calcium blocker use and breast cancer.

Other observational analyses also have indicated a link between short-acting calcium channel blockers and cancer risk in older persons. Studies in the August 24, 1996 issue of The Lancet and the July 1996 issue of the American Journal of Hypertension found a significantly greater risk of cancer from short-acting calcium blockers than from beta blockers and ACE inhibitors, other high blood pressure medications.

Short-acting calcium channel blockers also have been linked with an increased risk of death from heart attack. This evidence led the NHLBI to warn physicians in September 1995 that one particular calcium channel blocker--short-acting nifedipine--should be prescribed "with great caution (if at all)" because of the increased risk of death from its use.

But more research is needed to confirm a relationship between calcium channel blockers and cancer. The NCI is funding research on calcium blockers and their possible association with breast cancer.

Findings from clinical trials are especially important. Ongoing, randomized, controlled clinical trials are being funded, including the NHLBI-sponsored ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). ALLHAT includes only a longer-acting calcium channel blocker. These trials are carefully monitored by independent experts to insure patient safety and drug efficacy.

NIH/National Heart, Lung and Blood Institute

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.